Results 61 to 70 of about 26,835 (181)
BRAF inhibitor and hairy cell leukemia-related transient acantholytic dermatosis [PDF]
, 2020 Grover disease (GD) is an acquired, nonfamilial, nonimmune mediated, transient or persistent acantholytic dermatosis. Herein, we present a 72-year-old man who had clinical and histopathologic findings of GD following two weeks of treatment with ...
Durkin, John R +3 more
core
Emerging treatment options for BRAF-mutant colorectal cancer. [PDF]
, 2018 The personalization of cancer care is rooted in the premise that there are subsets of patients with tumors harboring clinically relevant targets for patient-specific treatments.
Atreya, Chloe E +2 more
core +2 more sources
International Journal of Cancer, Volume 158, Issue 9, Page 2418-2428, 1 May 2026.What's new? Cavity carcinomatosis, a late manifestation of cancer, fuels tumor formation throughout a large area, most commonly the peritoneal and pleural cavities. The condition also can lead to resistance to otherwise effective treatment strategies.
Zhongqiao Lin +6 more
wiley +1 more source
Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma. [PDF]
PLoS ONE, 2013 Treatment of metastatic malignant melanoma patients harboring BRAF(V600E) has improved drastically after the discovery of the BRAF inhibitor, vemurafenib.
Andliena Tahiri +8 more
doaj +1 more source
Pediatric Hematology Oncology Journal, 2021 Introduction: BRAF V600 E mutation is present in 50% cases of LCH and is associated with aggressive forms of disease-particularly liver dysfunction in infants and younger children.
Purva Kanvinde +8 more
doaj +1 more source
Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model. [PDF]
, 2016 Melanoma is a recalcitrant disease. The present study used a patient-derived orthotopic xenograft (PDOX) model of melanoma to test sensitivity to three molecularly-targeted drugs and one standard chemotherapeutic.
Chmielowski, Bartosz +11 more
core +1 more source
USP35 Acts as a Deubiquitinating Enzyme for ID3 to Promote Immune Escape in Colorectal Cancer
Advanced Science, Volume 13, Issue 16, 18 March 2026.USP35 stabilizes ID3 expression by deubiquitinating the K2/K30 site, thereby upregulating PD‐L1 and promoting immune escape in colorectal cancer. IU1, an inhibitor of USP35 enzyme activity, has been shown to inhibit USP35, thereby accelerating ID3 degradation, enhancing CD8+ T cell killing, and reversing the immunosuppressive microenvironment ...
Wenxin Chen +9 more
wiley +1 more source
Качественная клиническая практика, 2018 Aim. To perform health-economic evaluation of vemurafenib in comparison to dabrafenib in patients with metastatic or unresectable melanoma with BRAF V600 mutation in Russia from the healthcare system perspective. Materials and methods.
A. S. Kolbin +3 more
doaj
Cancer Reports, Volume 9, Issue 3, March 2026.ABSTRACT Background Pleomorphic xanthoastrocytomas (PXAs) are rare primary central nervous system (CNS) tumors that appear heterogeneous on imaging and histology and typically cause headaches or seizures on initial presentation. Alongside high rates of favorable prognosis after surgical excision exist similarly high rates of recurrence.
Randy S. D'Amico +8 more
wiley +1 more source
Guided Sample Pooling in Human Mass Balance Studies: A Recommended Strategic Decision Framework
Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 591-597, March 2026.Radiolabeled human mass balance studies are crucial for identifying circulating metabolites and understanding drug absorption, excretion, and clearance pathways. Metabolite profiling involves quantifying all drug‐related entities, including parent drug and metabolites in plasma and excreta, using extended liquid chromatography methods coupled with ...
Filip Cuyckens +21 more
wiley +1 more source